Monoclonal Antibodies Production, Diagnostic and Therapeutic Applications
نویسندگان
چکیده
منابع مشابه
Therapeutic Applications of Monoclonal Antibodies in Multiple Sclerosis
Despite the various therapies available, the use of monoclonal antibodies is a highly specific approach that has only recently been of interest to researchers. The properties of antibodies have led to their use in the treatment of various diseases, including cancer, Alzheimer's disease, diabetes and multiple sclerosis (MS). MS, a chronic inflammatory disease, occurs commonly in young adults. Th...
متن کاملMonoclonal Antibodies as Therapeutic Agents: Advances and Challenges
Despite the major advances in conventional forms of treatment (i.e. surgical techniques, radiotherapy and chemotherapy) and improved survival rates, cancer is still the second leading cause of death in developing countries. One major limitation of cytotoxic drugs and radiation in the treatment of cancer patients is their inability to discriminate between malignant and normal tissues. This in tu...
متن کاملProduction and Partial Characterization of Monoclonal Antibodies to Leishmania
Background: Monoclonal antibody technology allows identification of amastigote-specific antigen in human tissue biopsies and search for a suitable vaccine candidate, which may induce a long lasting immunity. Objectives: Production and partial characterization of seven monoclonal antibodies against Leishmania tropica promstigotes. Methods: Seven murine monoclonal antibodies of the IgG isotype we...
متن کاملMonoclonal Antibodies
SUMMARY Monoclonal Antibodies are identical antibodies and Can be generated in ultimated amounts by countinuos cultures of single antibody- secreting cells. These cell lines are produced by cell fusion of normal lymphocytes to cells of a myeloma tumor cell line, which confers on the antibody producing hybrid cell, immortality and the ability grow as atumor in animals. monoclonal antibodies c...
متن کاملBiosimilar Therapeutic Monoclonal Antibodies
Last month, Part 1 of this discussion brief ly described the regulatory landscape for developing biosimilar therapeutic monoclonal antibodies (TMAbs). We identified certain specific structural components of TMAb drug substances that warrant particular attention because alterations to them are likely to affect therapeutic safety and effectiveness. Now we conclude by considering whether studies o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Sohag Medical Journal
سال: 2018
ISSN: 1687-8353
DOI: 10.21608/smj.2018.39245